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Abstract: Intraocular lens development is driven by higher patient expectations for ideal 
visual outcomes. The recently US Food and Drug Administration-approved Softec HD™ 
lens is an aspheric, hydrophilic acrylic intraocular lens (IOL). The hydrophilic design of the 
lens is optimized to address dysphotopsia while maintaining biocompatibility, optical clarity, 
resistance to damage, and resistance to biocontamination. Aspheric lenses decrease postoperative 
spherical aberration. The addition of the Softec lens provides clinicians with another option for 
IOL placement; however, randomized comparative studies of this lens to others already on the 
market remain to be completed.
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Overview
The Softec HD™ posterior chamber intraocular lens (Lenstec Inc., St. Petersburg, FL, 
USA) is an ultraviolet (UV)-absorbing, single-piece modified “C” loop intraocular 
lens (IOL) with a symmetrical anterior and posterior surface aspheric design (zero 
aberration) (Figure 1). The Lenstec Softec HD IOL is manufactured completely from 
a medical-grade copolymer of hydrophilic acrylic hydroxyethylmethacrylate (HEMA, 
26% water content) and a polymerizable UV blocker. The overall length of the lens 
is 12.0 mm. The 5.5-mm-long lens optic has a 360° square edge design, designed for 
placement in the capsular bag. This lens is offered in power options in 0.25-D steps 
across the +18 to +25 D range, allowing more precise power correction.1
Although the Softec HD intraocular lens has been implanted in Europe since 2005, 
it was approved by the US Food and Drug Administration (FDA) in April 2010. This 
report summarizes the available information on the key characteristics of Softec HD 
IOLs, including biocompatibility, precision, optical clarity, and stability.
Advantages of hydrophilic acrylic material
Despite a decade of popularity elsewhere, hydrophilic acrylic IOLs have not gained 
popularity in the US due to several early reports of calcification and opacification.2–9 
Recently, a new generation of hydrophilic acrylic IOLs has been approved by the FDA 
and is now available for clinical use in the US.
Hydrophilic acrylics offer physical, biological, and optical qualities that make them 
suitable for use in foldable IOLs. These characteristics include the following:
1.  Less dysphotopsia: Hydrophilic acrylic IOLs have higher water content and 
therefore a decreased refractive index relative to hydrophobic IOLs, minimizing Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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problems with glare, external and internal reflections, and 
other unwanted visual phenomena.10–12
2.  Good biocompatibility: Khan and Percival13 followed 
patients with hydrophilic IOLs for 12 years and reported 
good flexibility and biocompatibility with minimal 
inflammatory reaction in the eye. These IOLs have less 
effect on the blood–aqueous barrier and may be a better 
option for uveitic and diabetic patients.
3.  Good optical clarity: Despite the early reports of calcifica-
tion in a few types of hydrophilic IOLs,14 new hydrophilic 
IOLs have different copolymer composition,1 and there 
have not been any reports of calcification or glistening 
in the last 5 years.
4.  Resistance to damage during insertion: Hydrophilic 
acrylic IOLs resist fold marks and forcep damage in 
contrast to silicone or hydrophobic IOLs.
5.  Less susceptibility to biocontamination: Schauers-
berger et al15 exposed nine different types of IOLs to 
standardized suspensions of Staphylococcus epider-
midis for 5 minutes, then rinsed and tested them for the 
presence of bacteria. Poly(methyl methacrylate) and 
hydrophobic IOLs had bacterial densities two or more 
times higher than hydrophilic IOLs. Schauersberger 
et al15 concluded that hydrophilicity of IOL material 
was inversely related to adhesion and bacterial density 
on the IOL surface.
Advantages of zero aberration 
aspherical IOLs
Several studies16–19 have shown that aspheric IOLs can 
provide patients with significant optical benefits over 
traditional spherical surface IOLs. These optical benefits 
are due to a reduction in optical aberrations, especially 
spherical aberration at the retina. The mean corneal spherical 
aberration is about +0.27 microns20 (90% of the population 
have positive corneal spherical aberration, whereas 10% have 
negative corneal spherical aberration).21
A biconvex IOL with spherical surfaces exhibits 
positive spherical aberration. Thus, usually, spherical IOLs 
add positive spherical aberration to the already positive 
corneal spherical aberration. Aspheric IOLs attempt to 
improve pseudophakic vision by controlling spherical 
aberrations. One strategy is to design a lens with negative 
spherical aberrations to balance the normally positive 
corneal spherical aberrations. Another strategy is to design 
a lens with minimum spherical aberrations (symmetric 
versus asymmetric conic surface) so that no additional 
spherical aberration is added to the corneal spherical 
aberrations.
Dr Sarver22 used a Kooijman20 eye model to compare 
the performance of different aspheric and spheric design 
IOLs in different settings, including lens decentration, 
lens tilt, and photopic and scotopic conditions. In this 
model, when the lens was centered, the spherical IOL 
performed worst and the negative spherical aberration 
IOL performed best. In cases of 1.0 mm decentration, the 
spherical surface and negative spherical aberration IOLs 
did not perform as well as zero aberration IOL designs, 
even when the trends for decentration did not depend on 
pupil size or corneal eccentricity. When considering tilt-
ing of the IOL, the performance of the IOL designs were 
comparable in most cases. The zero spherical aberration 
IOLs outperformed the spherical surface and negative 
spherical aberration IOLs.
In cases of 0.5 D of defocus at 3.0 and 5.0 mm pupils, 
the performances of all IOLs were about equal. The negative 
spherical aberration IOL showed more contrast for low-
frequency objects than the other IOLs did. The negative 
spherical aberration IOL showed significant regions of 
contrast reversal at 5.0 mm pupils. The equal conic IOL 
and unequal conic IOL designs appeared to perform about 
the same.
There are specific conditions in which one IOL design 
will perform better than another, but, generally, aspheric IOLs 
perform better than spherical surface IOLs. For the level of 
alignment errors, zero spherical aberration IOLs perform 
better than spherical surface IOLs and negative spherical 
aberration IOLs. The equal and unequal conic IOL designs 
perform similarly. The equal conic IOL design performs 
slightly better than the unequal conic IOL design in terms 
Figure 1 Softec HD lens (image provided by Lenstec inc., St. Petersburg, FL, USA).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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of smaller variability in tangential and sagital modulation 
transfer function (MTF) components in different settings, 
including decentration and tilt.24
Advantages of 0.25 D increments  
in IOL power
Approximately 12 to 15 million patients receive an IOL 
implantation each year.25 These patients are becom-
ing increasingly more demanding of higher-quality 
vision. Advances in surgical technique, better biometry, 
fourth-generation IOL calculation formulae, and recent 
advances in IOL design and manufacture have enabled 
surgeons  to  routinely  achieve  a  high  standard  of   
outcomes.
The International Organization for Standardization 
(ISO)25 has aided by setting standards for IOL manufacturing 
tolerances. The ISO benchmarks, however, have not been 
recently updated and tolerate a wide range of variability 
(Table 1). Although all manufacturers claim to exceed 
these tolerances,25 Lenstec’s range of accepted variability 
is smaller. The Softec HD aspheric lens seeks to create the 
most accurate aspheric IOL, available in 0.25 D increments 
from 18.00 to 25.00 D. It is also available in 0.50 D incre-
ments from 10.50 to 29.50 D and 1.00 D increments from 
5.00 to 36.00 D.
Lenstec preclinical studies
Lenstec Inc. performed nonclinical studies on this device in 
accordance with the ISO 11979 standards for IOLs.26
Biocompatibility studies
Lenstec Inc. conducted a series of in vivo and in vitro 
acute and chronic toxicity tests to establish the biocom-
patibility of the lens materials. In summary, the IOL 
material was nonmutagenic, nongenotoxic, nontoxic, 
and nonirritant after muscle implantation. The IOL 
was photostable and   nonextractable with a low level of   
aluminum.
Laboratory studies and manufacturing
Data from engineering analyses demonstrate the suit-
ability of the material and overall device design for use 
in IOLs. In summary, dioptric power, imaging qual-
ity/resolution, and spectral transmittance were within 
  acceptance   criteria. All lenses had an MTF value of 
greater than 0.43. All   dimensions and compression forces 
were within the designed acceptance criteria. In an eye 
model, average axial displacement was 0.1 mm, average 
decentration was 0.152 mm, and average optic tilt was   
1.58°.
FDA clinical studies in the US26
The multicenter US Lenstec Softec HD Posterior 
Chamber Intraocular Lens (PCIOL) Clinical Investiga-
tion was conducted at eight clinical centers with Softec 
HD PCIOL implantations occurring between December 
13, 2006 and June 9, 2008. One year postoperative 
follow-up provides documented evidence of the safety 
and effectiveness of the Softec HD PCIOL in 390 eyes 
of 390 study subjects.
Safety results
The analysis of safety was based on the cohort of 366 
patients who were available for the 12-month evaluation. 
The analysis of safety was based on adverse event rates 
(Table 2).
Effectiveness results
The analysis of effectiveness was based on visual acu-
ity on 366 patients at the 12-month time point. Of those 
patients implanted with the Softec HD IOL, 97.1% 
achieved a best-corrected visual acuity (BCVA) and 96.4% 
overall visual acuity of 20/40 or better as compared with 
the FDA grid (historical controls of 96.7% and 92.5%, 
Table 1 iSO manufacturing tolerance for iOLs versus Lenstec 
tolerance
Range of  
diopteric effect
ISO permitted  
tolerance
Softec HD   
lens
0 to #15 D ±0.3 D ±0.125 D
.15 to #25 D ±0.4 D ±0.125 D
.25 to #30 D ±0.5 D ±0.125 D
.30 D ±1.0 D ±0.125 D
Abbreviations: iSO, international Organization for Standardization; iOLs, intraocular 
lenses.
Table 2 Cumulative adverse events (occurring at any time during 
the study)
Cumulative  
adverse event
Softec HD  
incidence (%)  
N = 366
Food and Drug  
Administration   
grid (%)
Hyphema 0.0 2.2
Macular edema 0.8 3.0
Retinal detachment 0.0 0.3
Pupillary block 0.0 0.1
Lens dislocation 0.0 0.1
Endophthalmitis 0.0 0.1
Hypopyon 0.0 0.3
Surgical reintervention 0.0 0.8Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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respectively. The rate of 20/40 or better visual acuity 
for the cohort population exceeded the FDA grid values   
(Table 3).
Subgroup analyses
Additional safety analyses were conducted to look for trends 
that may not be apparent from the overall analysis of the 
adverse event and best spectacle corrected visual acuity rates. 
The following clinical data were evaluated.
Best-corrected distance visual acuity: 
stratified by age (all eyes)
BCVA stratified by age (age groupings: ,60 years; 
60 to ,70 years; 70 to ,80 years; and $80 years) at 
12-month follow-up. As would be anticipated, the proportion 
of eyes with BCVA $ 20/40 decreased with age: ,60 years 
(100%); 60 to ,70 years (99.2%); 70 to ,80 years (98.1%); 
and $80 years (95.7%).
Best-corrected distance visual acuity: 
stratified by adverse event
The sponsor performed an analysis of the best-corrected dis-
tance visual acuity stratified by the presence of any adverse 
event, or specifically for the presence of a haptic break.
The BCVA of subjects who experienced an adverse 
event as compared with those who did not was worse with 
regard to proportion of 20/40 or better vision. At 1 year, 87.5% 
in the adverse event group compared with 98.9% in the non-
adverse event group had BCVA of .20/40. One   hundred 
percent of cases in the adverse event group could see 20/50 
or better compared with 98.9% in the non-adverse event 
group. For those six study subjects who experienced a haptic 
break at the time of the Softec HD implantation and then 
received a Softec PCIOL, the 1 year BCVA was actually 
better compared with the total study subject population in 
the Softec HD cohort who did not experience a haptic break: 
100% haptic break group; 98.4% non-haptic break group 
seeing 20/40 or better. The occurrence of a haptic break had 
no impact on visual acuity.
Best-corrected distance visual  
acuity: stratified by preoperative  
ocular pathology
In the patient population, preoperative macular degenera-
tion was present in 3.1% and other pre-existing conditions 
existed in 30.5%. BCVA greater than 20/40 was lower in 
those study subjects with preoperative ocular pathology 
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(94.1%) compared with the group of study subjects with 
no preoperative ocular pathology (98.8%) at the study 
endpoint.
Best-corrected distance visual acuity: 
decrease of two or more lines
Forty-two subjects were included in a dateline listing of a decrease 
of two or more lines of BCVA. The distance BCVA was 20/40 
or better in 34 of the 42 subjects (81.0%). A clinical diagnostic 
explanation for the decrease in BCVA of two or more lines was 
identified by the   sponsor.   Thirty-seven of 42 subjects (88.1%) had 
a definitive   clinical   diagnosis that affected visual acuity. In the 
five cases with no definitive clinical explanation, the decreases 
in BCVA were as follows: 20/10 to 20/20 (pre-op 20/30); 20/20 
to 20/30 (pre-op 20/25); 20/20 to 20/30 (pre-op 20/50); 20/25 to 
20/40 (pre-op 20/50); and 20/25 to 20/40 (pre-op 20/50).
Best-corrected distance visual acuity: 
stratified by investigator
There was no statistically significant difference among sites with 
regard to BCVA 20/40 or better at 12 months (P = 0.24).
The future
There is an increasing expectation for the development of 
customized aspheric IOLs according to spherical aberration 
and patient pupil size. With more hydrophilic IOLs launch-
ing in the US market, there is anticipation of the marketing 
of rolling IOLs. Rolling IOLs can be inserted through a 
2 mm incision or smaller, thereby increasing the popularity 
of microincision cataract surgery.
Unfortunately, as of yet, no clinical study has been con-
ducted with the Softec HD IOL to assess the effect of the 
aspheric surface on spherical aberration, contrast sensitivity, 
and visual acuity in different distances and compare this 
lens with other types of aspherical and spherical IOLs in a 
randomized clinical trial. Such a future study would allow 
clinicians to have available to them the information needed 
to choose an appropriate IOL for each patient.
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